Overview

Harmony Biosciences: Who We Are

At Harmony Biosciences, we believe that when empathy and innovation meet, a better future can begin; a vision evident in the therapeutic innovations we advance, the culture we cultivate, and the community programs we nurture.

A woman sitting in her wheelchair outside

A New Era of Newrology

As Harmony Biosciences has expanded its commitment to the rare disease community in recent years, our mission remains the same: deliver innovative and novel treatments, while guided by our core principles of empathy and innovation.

Leaving conventional wisdom behind, Newrology represents Harmony Biosciences’ fresh approach to helping patients thrive today and into the future. By bringing together the perspectives and expertise of patients, families, advocates, specialists, innovators and scientists, we’ve created the harmony needed to move therapeutics and patient-kind forward in profound ways.

How Harmony Happens

2017
Harmony Biosciences is founded
2019
Harmony Biosciences received FDA approval for its first commercial product
2020
Harmony Biosciences joined the NASDAQ with its IPO launch
2021
Harmony Biosciences added to the S&P SmallCap 600® Index and the NASDAQ Biotechnology Index
2022
Harmony Biosciences signed agreement with Bioprojet focused on developing innovative therapeutics to expand opportunity in narcolepsy
2023
Harmony Biosciences acquired Zynerba Pharmaceuticals
2024
Harmony Biosciences acquired Epygenix Therapeutics
Join the Team

Join the Team

Interested in creating a better future for rare neurological disease communities? Harmony Biosciences is hiring.

Work at Harmony